mRNA-Based Therapeutics and Vaccines in Atherosclerosis and Coronary Artery Disease: Emerging Immunomodulatory Strategies
Adwetia Garg
21/11/26
Atherosclerosis and coronary artery disease are two of the most severe cardiovascular conditions, which include lipid accumulation, endothelial dysfunction, chronic inflammation, and plaque instability. Although various medications are used to treat these conditions, such as statins, PCSK9 inhibitors, and anti-inflammatory agents, they don't always react positively in all patients. Some do not respond, and they cannot target all stages of disease development. Therefore, RNA-based therapy has become a novel treatment option for most cardiovascular diseases. The messenger RNA technology provides instructions for a cell to produce certain therapeutic proteins and can also be utilized in a sort of vaccine manner to modulate the immune system. In cardiovascular disease, specifically atherosclerosis and coronary artery disease, mRNA platforms are being investigated for potential applications in lipid metabolism and vascular immunomodulation. Immunomodulation includes regulation of T cells, including the balance between pro-inflammatory T cells and regulatory T cells (Tregs), as well as cytokine levels, like IL-1β, IL-6, and TNF-α. Accessible evidence suggests positive results in laboratory studies and some patient data regarding VEGF-A mRNA treatments. However, there are still several issues related to delivery, safety, activation, and sustainability of mRNA therapy. In the foreseeable future, research may involve investigation of vaccines, nanotechnology, combination therapy, and precision immunotherapy.
